Author: Customer Service

Schindellegi, Switzerland – 19 October 2026 Trifork Group AGCompany announcement no. 63/2026 Weekly report on share buyback On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million). Under the program, the following transactions have been made:Date                                        Number of shares        Average purchase price (DKK)        Transaction...

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,180,726 960.58 2,094,770,43712 October 2026 10,999 1,089.19 11,980,03413 October 2026 11,061 1,081.67 11,964,40214 October 2026 11,171 1,068.06 11,931,29015...

Global Intelligent Luxury Mobility Set Sail From Here WUHU, China, Oct. 19, 2026 (GLOBE NEWSWIRE) — From October 18 to 24, the 2026 Chery International User Summit kicked off in Wuhu, Anhui. Under the theme “High Tech for Our Future Life,” the summit brings together users, partners, and media representatives from numerous countries and regions worldwide, presenting Chery Group’s future-oriented strategic vision and tangible achievements centered on the evolution of mobility in the intelligent era. As a pivotal chapter of the summit, a series of events for LUXEED, the all-new intelligent luxury brand, commenced simultaneously.Brand Foundation: Redefining Luxury Through Intelligence LUXEED is an intelligent luxury brand grounded in a global perspective. Anchored by its core pillars of “Extreme Driving Pleasure, Beyond-Class Enjoyment,...

Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. Nákvæmnismeðferðarnálgun á stórum markaði: Licaminlimab gæti orðið fyrsta nákvæmnislyfjameðferðin sinnar tegundar fyrir rúmlega 1,5 milljón sjúklinga í Bandaríkjunum sem áætlað er að séu með miðlungs til alvarlegan TNFR1-miðlaðan augnþurrk (e. Dry Eye Disease, DED)1-4, og mætt þannig brýnni óuppfylltri þörf á sviði sem í gegnum tíðina hefur einkennst af ólíkum sjúklingahópum. Mikilvægur áfangi á áætlun: Gert er ráð fyrir að fyrstu niðurstöður (e. topline data) úr þessari fyrstu skráningarrannsókn á augnþurrki sem byggir á arfgerð liggi fyrir í kringum árslok 2026. ZUG, Sviss, 19 október, 2026 — Oculis Holding AG (Nasdaq:...

19 October 2026 – Alstom, a global leader in smart and sustainable mobility, has secured a first tranche order worth approximately €800 million for the supply of Metropolis trains for urban rail projects in Hanoi, as part of the agreement announced on 6 October 2026 with Vingroup (see link). The trains will be designed and manufactured at Alstom’s Valenciennes Petite-Forêt site in France. This first tranche order will be booked in the third quarter of Alstom’s fiscal year 2026/27. Metropolis™, Alstom™ are protected trademarks of the Alstom Group. About Alstom Alstom is the pure rail leader, committed to making rail the backbone of sustainable transportation. We design and deliver a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end...

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital. Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme. The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters...

The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market. Louvain-la-Neuve, Belgium, Paris, France, Indianapolis, United States, and Melbourne, Australia, October 19th, 2026, 7 a.m. – Ekalia (company in formation), the joint venture combining IBA’s technological expertise (Ion Beam Applications, EURONEXT) with Framatome’s industrial know-how, has entered into a collaboration agreement with Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”), a global leader in radiopharmaceuticals, aimed at accelerating the production of Astatine-211 (At-211) in the United States. Following Ekalia’s planned first site in France, this collaboration marks an important step in the development of a robust, reliable and international infrastructure to support...

Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid OSE Immunotherapeutics to host a KOL webcast on November 4, 2026Nantes, France, October 19, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced the release of the abstract selected for an oral presentation at the upcoming ESMO 2026 Annual Meeting, unveiling topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi® sponsored by FoRT and evaluating Tedopi® (OSE2101), in combination with either chemotherapy or anti-PD1, as a 2nd line treatment in patients with metastatic...